Tharimmune, Inc.
PublicTharimmune, Inc. is now publicly traded
The data on this page reflects Tharimmune, Inc.'s private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Private Placement
Nov 6, 2025
Total Funding Raised
$540M
Company Overview
Tharimmune, Inc. is a clinical-stage biotechnology company that develops a portfolio of therapeutic candidates for inflammatory and immunologic conditions and also operates a digital asset treasury strategy.
AI Layer
Non-AI
Keywords
Tharimmune, Inc. Comparables
Compare Tharimmune, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Avior Bio, Inc. | 77% | |
| Attovia Therapeutics | 59% | |
| ItchBio | 59% |
Tharimmune, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Nov 6, 2025 |
Tharimmune, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Feynman Point Asset Management | Private Placement |
| Nima Capital | Private Placement |
| Polychain Capital | Private Placement |
| DRW Trading Group | Private Placement |
| Liberty City Ventures | Private Placement |
| 7Ridge | Private Placement |
| Five North | Private Placement |
Tharimmune, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access